Updated on 26 November 2015
Tokyo: Tokyo-headquartered Solasia Pharma KK and Hong Kong's Lee's Pharmaceutical Holdings Limited jointly announced today that Solasia and Lee's Pharma have entered into an exclusive license agreement for the commercialization and promotion of Sancuso (granisetron transdermal delivery system) in the People's Republic of China (PRC) excluding Taiwan, Hong Kong, Macau and the Retained Territory.
Solasia will retain rights to promote Sancuso in three major cities (Beijing, Shanghai and Guangzhou - the Retained Territory) in the PRC.
Under the terms of the Agreement, Solasia granted Lee's Pharma an exclusive license and right for promoting, commercializing, distributing and selling Sancuso in the licensed territory for the patients suffering from chemotherapy-induced nausea vomiting (CINV) caused by chemotherapy. Solasia obtained an exclusive license to develop and commercialize Sancuso for Asian territories from ProStrakan and is currently waiting for approval from the China Food and Drug Administration.
"We are extremely excited to enter into an exclusive partnership with Lee's Pharma for Sancuso. As we prepare for commercialization in the PRC, we believe our creative partnership would enable us to cover a large part of mainland China to support cancer patients going through chemotherapy," said Yoshihiro Arai, President & Representative Director. "CINV is still a difficult symptom to control for patients receiving chemotherapy. Sancuso with its uniqueness of transdermal delivery system, we hope to change the treatment paradigm."
Sancuso is an extended release transdermal system, delivering the anti-emetic, granisetron, steadily into the patient's bloodstream over several days without the need for injections or swallowing pills.
Granisetron is a 5-HT3 receptor antagonist with well-established efficacy against chemotherapy-induced nausea and vomiting (CINV). Sancuso was approved by the U.S. Food & Drug Administration (FDA) in September 2008 for the prevention of CINV in patients receiving moderately and/or highly emetogenic chemotherapy for up to 5 consecutive days. Sancuso was launched in the US in 2008 and 2013 in the EU.